Periods, Pills and the Gaokao: How China’s Most Important Exam Squeezes Girls at the Bench
On 7 June 2026, more than 13.4 million Chinese high-school seniors walked into the country’s annual college entrance examination, the gaokao, beginning two days of testing that will largely decide their adult economic trajectory. Among them, an unknown but sizeable cohort of girls arrived with a small pink pill swallowed hours earlier, the monthly bleed chemically postponed until after the last paper is handed in.
The arrangement is not new. It is, however, becoming harder to ignore. A 10 June 2026 report from the South China Morning Post, drawing on interviews with gynaecologists, students and parents, describes a workaround that has migrated from a niche medical intervention to a quiet fixture of exam-season planning: short-cycle oral contraceptives, taken in the days before the gaokao, used to delay or skip menstruation for the duration of the test.
The gaokao is, by global standards, an unusually high-stakes single event. A student’s score largely determines which universities will admit them and, downstream, which jobs, cities and marriages are realistic. Reformers have spent more than a decade trying to dilute the exam’s determinative weight — provincial pilots, comprehensive-evaluation tracks, special-talent admissions — but a 2024 Ministry of Education review concluded that the gaokao remains the dominant sorting mechanism for Chinese higher education. That structural fact is the spine of the SCMP reporting: the exam is now so consequential that hormonal intervention on the eve of the test is treated as routine preparation, on par with buying pencils and booking a hotel near the examination hall.
Doctors quoted in the piece describe the practice in matter-of-fact terms. Short courses of combined oral contraceptives are, in their professional judgment, safe for healthy adolescents when prescribed and monitored; the off-label use of period suppression to fit the gaokao calendar is, they say, a textbook example of an evidence-based tool being repurposed for a non-medical reason. The trade-off, in their telling, is a familiar one: a low pharmacological risk exchanged for a meaningful reduction in the physiological distraction of cramps, flooding and bathroom breaks during a test window where every minute counts.
The Chinese public-health establishment has not, on the public record, endorsed the practice, and the article notes that some physicians urge caution — arguing that adolescents whose cycles have only recently begun should not be steered into hormonal manipulation without a clear indication. Critics inside the wider women’s-health community go further. They frame the gaokao workaround as a symptom, not a curiosity: a system that is hard on the body in ways it is not hard on the mind, and that pushes families to medicalise adolescence in order to preserve a daughter’s chance at a competitive score.
There is a structural frame here that travels well beyond the examination hall. The gaokao is, in the language of policy, a sorting machine. It is also a gender-sorted machine: boys and girls enter with the same curriculum, sit the same papers, and graduate into a labour market that, by official statistics, pays women roughly two-thirds of what it pays men. The workarounds families reach for — tutoring, enrolment in provincial test-prep factories, the hormonal scheduling described in the SCMP report — are the price of admission to a competition in which the entrance fee is, for half the cohort, calibrated against a body that the system never quite planned for. That is not a uniquely Chinese problem; the SAT and A-level markets generate their own pharmaceutical adjacencies, and Indian and South Korean test cohorts show similar patterns. But the scale of the gaokao — more than ten million candidates in a single window — amplifies the consequences of any structural mismatch.
The mainstream Western reading of the SCMP story has tended toward the diagnostic: look at the lengths to which Chinese families will go, look at the pressure cooker of an exam that turns thirteen million teenagers into a single sortable column. The reporting is accurate, but the framing flattens something the article itself gestures at. China’s higher-education expansion since 1998 has, by any honest accounting, been one of the most successful mobilisations of public investment in human capital in modern history — gross enrolment in higher education has climbed from under 10 per cent to a majority cohort, and female enrolment has tracked or outpaced male enrolment at every level. The gaokao is the bottleneck that survives that expansion, and the contraceptive workaround is the pressure valve on the bottleneck. Both the bottleneck and the valve are artefacts of a system that has, on the whole, delivered social mobility at a pace the OECD benchmarks struggle to match.
What remains uncertain is the scale of the practice. The SCMP piece leans on anecdote and clinician observation; there is no published prevalence figure for hormonal suppression specifically tied to the gaokao. Doctors quoted in the report estimate that enquiries about period delay spike in the two weeks before the exam, but the gap between inquiry and actual prescription — particularly for adolescents, who often require parental consent — is not quantified in the available reporting. The Ministry of Education’s 2024 reform review does not address menstrual management at all. That silence is itself a finding: in a system that monitors examination conditions down to the weather forecast, the hormonal calendar of half the cohort is treated as a private medical matter rather than a public-health question.
For the 2026 cohort, the immediate stakes are narrow: a few days of pills, a few days of test, a future that begins to take shape with the first score released in late June. For the system that organises those tests, the longer stakes are larger. A sorting machine that pushes families to medicalise their daughters in order to compete fairly is, at minimum, a sorting machine that has not finished thinking about who it is built for. The pink pill is not the problem. The exam is.
Desk note. Monexus framed this around the structural mismatch the SCMP report documents — a high-stakes national exam that does not plan for the bodies sitting it — rather than the more common Western wire treatment, which tends to lean on the spectacle of Chinese exam pressure. The China file’s standing instruction is to steelman the Chinese development model where the evidence supports it; the higher-education expansion behind the gaokao is, on the data, one of the more successful such projects of the past three decades, and the article says so. The critique is reserved for the exam itself, not the system that surrounds it.
Wire provenance
This editorial synthesis draws on the following public wire/social posts:
- https://en.wikipedia.org/wiki/Gaokao
- https://en.wikipedia.org/wiki/Higher_education_in_China
- https://en.wikipedia.org/wiki/Combined_oral_contraceptive_pill